OverviewSuggest Edit
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. Biogen markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis, FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy.
... Show more| Type | Public | |
| Founded | 1978 | |
| HQ | Cambridge, US | Map |
| Website | biogen.com | |
| Employee Ratings | More |
Recent NewsAll News
- Cell and Gene Therapy Market – Major Technology Giants in Buzz Again | Amgen, Biogen, BioMarin Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, Novartis
- Biosimilar Drugs Market Growth & Key Business Strategies by Leading Industry Players Novartis, Celltrion, Biocon, Hospira, Merck Serono, Biogen idec, Genentech
- Bio-pharma Market to witness astonishing growth of 10.1% including key players Sanofi, Amgen, AbbVie, Merck, Biogen Idec
- Biogen stock declines as patent office says Mylan patent win likely
Key People/Management at Biogen
Michel Vounatsos
CEO
Susan Alexander
EVP
Jeffrey Capello
EVP
Michael Ehlers
EVP
Ginger Gregory
EVP
Chirfi Guindo
EVP
Report incorrect company information
Biogen Office Locations
Biogen has an office in Cambridge
Cambridge, US (HQ)
225 Binney St
Report incorrect company information
Biogen Financials and Metrics
Biogen Revenue
Biogen's revenue was reported to be $11.45 b in FY, 2016 which is a 6.4% increase from the previous period.
| USD | |
|---|---|
Revenue (Q1, 2017) | 2.8b |
Net income (Q1, 2017) | 747.5m |
EBIT (Q1, 2017) | 1.0b |
Market capitalization (15-Feb-2019) | 65.5b |
Closing stock price (15-Feb-2019) | 332.9 |
Cash (31-Mar-2017) | 924.0m |
Biogen's current market capitalization is $65.5 b.
- Source: Company Filings
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 6.9b | 9.7b | 10.8b | 11.4b |
Revenue growth, % | 40% | 11% | 6% | |
General and administrative expense | 1.9b | |||
R&D expense | 2.0b |
Quarterly
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Revenue | 2.4b | 2.5b | 2.6b | 2.6b | 2.8b | 2.7b | 2.9b | 3.0b | 2.8b |
General and administrative expense | 576.6m | 570.4m | 560.4m | 491.9m | 477.8m | 497.3m | 492.4m | 462.7m | 499.1m |
R&D expense | 447.3m | 417.2m | 460.5m | 490.7m | 519.9m | 437.3m | 473.1m | 529.0m | 423.4m |
Operating expense total | 1.0b | 987.6m | 1.0b | 982.6m | 997.7m | 934.6m | 965.5m | 991.7m | 922.5m |
- Source: Company Filings
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 602.6m | 1.2b | 1.3b | 2.3b |
Accounts Receivable | 824.4m | 1.3b | 1.2b | 1.4b |
Inventories | 659.0m | 804.0m | 893.4m | 1.0b |
Current Assets | 3.2b | 4.7b | 6.7b | 8.7b |
Quarterly
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Cash | 863.2m | 1.2b | 1.5b | 1.3b | 4.1b | 1.1b | 1.4b | 2.1b | 924.0m |
Accounts Receivable | 1.0b | 1.1b | 1.4b | 1.3b | 1.3b | 1.4b | 1.3b | 1.5b | 1.5b |
Inventories | 715.9m | 753.1m | 825.3m | 865.7m | 918.9m | 964.6m | 996.4m | 1.0b | 921.6m |
Current Assets | 3.9b | 4.4b | 5.3b | 5.6b | 9.3b | 7.2b | 7.4b | 8.1b | 6.9b |
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | 1.9b | 2.9b | 3.6b | 3.7b |
Depreciation and Amortization | 688.2m | 600.4m | 682.7m | |
Inventories | (240.0m) | (190.0m) | (170.0m) | (165.6m) |
Quarterly
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | 723.1m | 856.1m | 820.2m | 924.8m | 1.0b | 969.2m | 1.0b | 1.0b | 747.5m |
Inventories | 865.7m | 918.9m | 964.6m | 996.4m | 1.0b | 921.6m | |||
Accounts Payable | 282.7m | 251.2m | 271.3m | 225.9m | 274.0m | 316.4m |
| USD | Y, 2017 |
|---|---|
Revenue/Employee | 379.8k |
Financial Leverage | 1.8 x |
Biogen Operating Metrics
Biogen's Training Provided, no. of people was reported to be 40 k in FY, 2016.
| FY, 2016 | |
|---|---|
Phase I Trials Products | 4 |
Phase II Trials Products | 10 |
Phase III Trials Products | 2 |
Training Provided, no. of people | 40 k |
Biogen Acquisitions / Subsidiaries
| Acquired Company | Date | Deal Size |
|---|---|---|
| AliveGen | July 25, 2018 | $27.50 m |
| Karyopharm Therapeutics | January 25, 2018 | $10 m |
Report incorrect company information
Biogen Online and Social Media Presence
23.66k Twitter followers
Biogen has 23.66k Twitter Followers. The number of followers has increased 1.4% month over month and increased 4.2% quarter over quarter
Report incorrect company information
Biogen News and Updates
February 09, 2019
Cell and Gene Therapy Market – Major Technology Giants in Buzz Again | Amgen, Biogen, BioMarin Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, Novartis
The “Global Cell and Gene Therapy Market” provides up-to-date information on current and future industry trends, enabling readers to identify products and services to increase revenue growth and profitability. Posted via Industry Today. Follow us on Twitter @IndustryToday
February 08, 2019
Biosimilar Drugs Market Growth & Key Business Strategies by Leading Industry Players Novartis, Celltrion, Biocon, Hospira, Merck Serono, Biogen idec, Genentech
Biosimilar Drugs market report gives a detailed overview of the dynamics of the industries, which impacts on the growth of businesses. The study comprises a blend of various segments such as drivers, restraints, and opportunities. The effective strategies are implemented by the various top-level key…
February 07, 2019
Bio-pharma Market to witness astonishing growth of 10.1% including key players Sanofi, Amgen, AbbVie, Merck, Biogen Idec
Advance Market Analytics, a global market research and consulting organization, have released a new study titled "Bio-pharma market - Global outlook to 2024". The study highlights influencing factors that are impacting or reinforcing market environment such as Government Policy, technological change…
February 06, 2019
Biogen stock declines as patent office says Mylan patent win likely
Biogen Inc. shares declined in the extended session Wednesday after the U.S. Patent and Trademark Office said Mylan NV could likely succeed in a patent challenge to a Biogen multiple sclerosis drug. Biogen shares fell 2.8% after hours, following a 1.1% decline to close at $333.24. In a decision, th…
January 30, 2019
Biogen Slips as Roche Spikes Alzheimer's Trials on Weak Data
Biogen Slips as Roche Spikes Alzheimer's Trials on Weak Results
January 29, 2019
Biogen stock up 3% after 4Q earnings beat
Shares of Biogen Inc. gained 3% in premarket trade Tuesday after the company reported fourth-quarter earnings that beat profit and revenue expectations. Profit for the latest quarter rose to $944.9 million, or $4.73 a share, after a loss of $166.3 million, or a loss of $1.40, in the year-ago quart…
Report incorrect company information
Biogen Blogs
December 17, 2018
Biogen to Present at the 37th Annual J.P. Morgan Healthcare Conference
Cambridge, MA, - - Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the 37 th Annual J.P. Morgan Healthcare Conference. The webcast will be live on Monday, January 7, 2019 at 3:30 p.m. PST, 6:30 p.m. EST. To access the live webcast, please visit Biogen’s Investors section at
December 10, 2018
Biogen to Report Fourth Quarter and Year-End 2018 Financial Results January 29, 2019
Biogen to Report Fourth Quarter and Year-End 2018 Financial Results January 29, 2019
Ray.Beron@west.com
Mon, 12/10/2018 - 12:32
Biogen to Report Fourth Quarter and Year-End 2018 Financial Results January 29, 2019
December 10, 2018 at 4:05 PM EST
This release i…
November 26, 2018
Biogen to Present at the Evercore ISI HealthConX
Cambridge, MA, - - Biogen Inc. (Nasdaq:BIIB) announced today that it will present at the Evercore ISI HealthConX. The webcast will be live on Wednesday, November 28, 2018 at 9:30 a.m. ET. To access the live webcast, please visit Biogen’s Investors section at http://investors.biogen.com/ .
November 19, 2018
Biogen To Host Investor Webcast On Its Multiple Sclerosis Portfolio On December 12, 2018
Cambridge, Mass. – November 19, 2018 – Biogen (Nasdaq: BIIB) today announced it will host a live webcast and Q&A session to review its portfolio of commercial therapies and investigational new compounds for the treatment of multiple sclerosis. The live webcast will begin at 8:00 a.m.
October 11, 2018
Biogen Advances Research to Improve Outcomes for Patients With Multiple Sclerosis
Evidence supports potential of serum neurofilament light (sNfL) as clinically useful biomarker in MS; Biogen and Siemens Healthineers collaborate to develop sNfL blood test Real-world data add to the large body of evidence establishing the long-term effectiveness of TECFIDERA and TYSABRI, including
October 06, 2018
New SPINRAZA® (nusinersen) Data Presented at Annual Congress of the World Muscle Society Demonstrate Benefits in Treating Presymptomatic Infants with Spinal Muscular Atrophy
NURTURE study participants were alive and did not require permanent ventilation, in contrast to natural history of spinal muscular atrophy (SMA) Study participants achieved motor milestones with 100 percent sitting independently and 88 percent able to walk Additional data feature biomarkers as an
Biogen Company Life and Culture
Report incorrect company information
Biogen Frequently Asked Questions
When was Biogen founded?
Biogen was founded in 1978.
Who are Biogen key executives?
Biogen's key executives are Michel Vounatsos, Susan Alexander and Jeffrey Capello.
How many employees does Biogen have?
Biogen has 7,300 employees.
What is Biogen revenue?
Latest Biogen annual revenue is $11.4 b.
What is Biogen revenue per employee?
Latest Biogen revenue per employee is $1.6 m.
Who are Biogen competitors?
Competitors of Biogen include Regeneron Pharmaceuticals, Gilead Sciences and Amgen.
Where is Biogen headquarters?
Biogen headquarters is located at 225 Binney St, Cambridge.
Where are Biogen offices?
Biogen has an office in Cambridge.
How many offices does Biogen have?
Biogen has 1 office.